21 February 2023EMACibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz: referral - article 20 procedureReferral - Article 20 procedureMedicine safety communications
17 February 2023EMANeofordex: change in dosing recommendationChange in dosing recommendationMedicine safety communications
14 February 2023EMAAdakveo: referral - article 20 procedureReferral - Article 20 procedureMedicine safety communications
8 February 2023EMAAmfepramone: referral - article 31Referral - Article 31Medicine safety communications
1 December 2022EMATerlipressin: referral - article 31Referral - Article 31Medicine safety communications
8 November 2022EMAZoely: adverse event;referral - article 31Adverse event;Referral - Article 31Medicine safety communications
3 November 2022EMAImbruvica: post-authorisation measurePost-authorisation measureMedicine safety communications
12 August 2022EMARubraca: referral - article 20 procedure;restriction of indicationReferral - Article 20 procedure;Restriction of indicationMedicine safety communications
11 August 2022EMAHiprabovis IBR Marker Live: adverse eventAdverse eventMedicine safety communications
30 June 2022EMAHydroxyethyl starch: post-authorisation measurePost-authorisation measureMedicine safety communications